Biocon's Q4 margin rebounds sequentially, but profit falls 56.77% YoY
Revenue grew 2.25% YoY, slower than expenses at 4.72%, while higher depreciation, interest and tax weighed on earnings.
Filed 08 May 2026, 00:16 IST · Biocon Ltd (BIOCON)
Key takeaways
- Q4 consolidated net profit fell 56.77% YoY to Rs 198.6 cr as profit before tax dropped 49.16%.
- Operating margin recovered 2.62 percentage points QoQ to 22.59%, but remained 1.82 percentage points below Q4FY25.
- The stock slipped 0.48% initially, versus a 1.43% median absolute move after the last eight results.
Price around the results
Sequential recovery cannot offset the year-on-year earnings squeeze
Biocon's consolidated revenue grew 2.25% YoY, but expenses rose 4.72%, pushing operating margin down 1.82 percentage points. Higher interest costs of 8.99% and depreciation of 17.67% added to the pressure below operating profit. The 8.23% QoQ revenue increase outpaced 4.70% expense growth, lifting operating margin by 2.62 percentage points.
Facility costs explain why margins remain below last year's level
Management said Generics margins reflected higher costs at recently commissioned facilities and that margins should gradually rebuild as revenue from those facilities ramps up. At 22.59%, Biocon's operating margin was 0.79 percentage points below the 23.38% median for 48 Healthcare peers that had reported the same quarter. The margin path improved from 19.00% in Q1FY26 to 22.59% in Q4FY26, but stayed below 24.41% in Q4FY25.
Negative other income and a higher tax rate weakened profit quality
Other income was negative Rs 27.9 cr, equivalent to -11.27% of profit before tax, so it provided no support to reported earnings. The tax rate rose 14.13 percentage points YoY to 19.76%, compared with 5.63% a year earlier, making the profit comparison harsher. Sequentially, the tax rate fell 3.84 percentage points, which aided the recovery from the previous quarter's loss.
Management points to pipeline expansion alongside the margin rebuild
The company said it had commenced operations at an ADC discovery laboratory and achieved GCP-NABL accreditation during FY26. Management also highlighted multiple biosimilar approvals and launches, along with Generics approvals for Everolimus in the US and Tacrolimus across Latin American markets. It said Yesintek remained the market leader among biosimilars and noted senior leadership appointments for its next phase of growth.
The initial market reaction was ordinary, but gains widened later
The stock opened with a 0.85% gap down and was down 0.48% on the result date, close to the 1.43% median absolute move after its last eight results. The reaction then turned positive, with the stock up 12.52% five sessions after the result and 11.35% after 15 sessions. Its past result-day reactions were evenly split between four rises and four falls.
Q4FY26 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 | Q3FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹4,517 cr | ₹4,173 cr | +8.23% | +2.25% |
| Other income | ₹-28 cr | ₹-176 cr | +84.16% | — |
| Expenses | ₹3,496 cr | ₹3,340 cr | +4.70% | +4.72% |
| Operating profit | ₹1,020 cr | ₹834 cr | +22.41% | -5.37% |
| Operating margin (%) | 22.59% | 19.97% | — | — |
| Interest | ₹232 cr | ₹210 cr | +10.29% | +8.99% |
| Depreciation | ₹513 cr | ₹515 cr | -0.37% | +17.67% |
| Profit before tax | ₹248 cr | ₹-68 cr | — | -49.16% |
| Tax | ₹49 cr | ₹-16 cr | — | +78.47% |
| Net profit | ₹199 cr | ₹-52 cr | — | -56.77% |
| EPS (₹) | ₹0.79 | ₹1.08 | -26.85% | -72.57% |
Operating margin of 22.59% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -0.48% | +0.13% |
| Next session | +2.15% | — |
| 5 sessions | +12.52% | +15.33% |
| 15 sessions | +11.35% | — |
| 30 sessions | +10.16% | — |
Volume on the results session was 1.84× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- Generics expects margins to gradually rebuild as revenues from recently commissioned facilities ramp up.
Expansion
- Biocon commenced operations at an ADC discovery laboratory.
New products
- The biosimilars portfolio expanded with multiple approvals and launches now in place.
- Generics received approval for Everolimus tablets in the U.S. and Tacrolimus across Latin American markets.
New initiatives
- Biocon achieved GCP-NABL accreditation during FY26.
- Senior leadership appointments were made to support Biocon's next phase of growth.
Competition
- Yesintek remained the market leader among biosimilars.
Problems & risks
- Generics margins reflected higher costs from recently commissioned facilities.
What to watch
- Whether operating margin holds above 22.59% after the 2.62-percentage-point QoQ recovery.
- Whether revenue growth improves from the 2.25% YoY pace while expense growth stays below 4.72%.
- Whether interest and depreciation growth moderate from 8.99% and 17.67% YoY, respectively.